Literature DB >> 21713580

The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.

Jennifer M J Schreinemakers1, Carolina R C Pieterman, Anouk Scholten, Menno R Vriens, Gerlof D Valk, Inne H M Borel Rinkes.   

Abstract

BACKGROUND: The optimal surgical approach for patients with primary hyperparathyroidism (pHPT) and multiple endocrine neoplasia 1 (MEN1) is controversial. We sought to determine the optimal type of surgery for pHPT in MEN1.
METHODS: We collected data on clinical presentation, surgery, and follow-up for MEN1 patients with pHPT at the University Medical Center Utrecht and affiliated hospitals between 1967 and 2008. Furthermore, we performed a systematic review of the literature and meta-analysis. Surgical procedures were classified into less than subtotal (<SPTX) versus subtotal (SPTX) and total parathyroidectomy (TPTX).
RESULTS: Fifty-two patients underwent primary surgery for pHPT, of which 29 had <SPTX, 17 SPTX, and 6 TPTX. Recurrent pHPT was most frequent after SPTX (65%) followed by <SPTX (59%). Persistent disease was most frequent after <SPTX (31%). Time to recurrence was 61 months longer after SPTX than after <SPTX. Although recurrent pHPT was not seen after TPTX, permanent hypoparathyroidism developed in 67% of these patients. The meta-analysis showed that after SPTX and TPTX, patients had the lowest risk of persistent and recurrent pHPT. TPTX had the highest risk of permanent hypoparathyroidism. Large noncomparative studies showed a low recurrence rate after SPTX and TPTX.
CONCLUSION: We believe that SPTX is the best surgical therapy for pHPT in MEN1. MEN1 patients with pHPT should not be treated with <SPTX because of the unacceptable high rate of recurrent and persistent pHPT. Additionally, a thymectomy should routinely be performed in these patients.

Entities:  

Mesh:

Year:  2011        PMID: 21713580     DOI: 10.1007/s00268-011-1068-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

Review 1.  Primary hyperparathyroidism in MEN 1--how radical should surgery be?

Authors:  Johnathan G H Hubbard; Frédéric Sebag; Sylvie Maweja; Jean-François Henry
Journal:  Langenbecks Arch Surg       Date:  2002-02-06       Impact factor: 3.445

2.  The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1.

Authors:  J R Burgess; R David; V Parameswaran; T M Greenaway; J J Shepherd
Journal:  Arch Surg       Date:  1998-02

3.  Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia types I and IIa: is a more or less extended operation essential?

Authors:  C Dotzenrath; K Cupisti; P E Goretzki; Q Yang; D Simon; C Ohmann; H D Röher
Journal:  Eur J Surg       Date:  2001-03

4.  Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Laura A Lambert; Suzanne E Shapiro; Jeffrey E Lee; Nancy D Perrier; Mylene Truong; Michael J Wallace; Ana O Hoff; Robert F Gagel; Douglas B Evans
Journal:  Arch Surg       Date:  2005-04

5.  Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1.

Authors:  Dina M Elaraj; Monica C Skarulis; Steven K Libutti; Jeffrey A Norton; David L Bartlett; James F Pingpank; Fathia Gibril; Lee S Weinstein; Robert T Jensen; Stephen J Marx; H Richard Alexander
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

Review 6.  The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1.

Authors:  S E Carty; A K Helm; J A Amico; M R Clarke; T P Foley; C G Watson; J J Mulvihill
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

7.  Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome.

Authors:  C R C Pieterman; J M J Schreinemakers; H P F Koppeschaar; M R Vriens; I H M Borel Rinkes; B A Zonnenberg; R B van der Luijt; G D Valk
Journal:  Clin Endocrinol (Oxf)       Date:  2008-06-25       Impact factor: 3.478

8.  Parathyroid hyperplasia in multiple endocrine neoplasia type 1: a pathological and immunohistochemical reappraisal.

Authors:  H R Harach; B Jasani
Journal:  Histopathology       Date:  1992-04       Impact factor: 5.087

9.  Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?

Authors:  Francesco Tonelli; Tommaso Marcucci; Geri Fratini; Maria Silvia Tommasi; Alberto Falchetti; Maria Luisa Brandi
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

10.  [Multiple endocrine neoplasia type 1. Surgical therapy of primary hyperparathyroidism].

Authors:  P Langer; A Wild; T Schilling; C Nies; M Rothmund; D K Bartsch
Journal:  Chirurg       Date:  2004-09       Impact factor: 0.955

View more
  23 in total

1.  Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.

Authors:  Manjunath Goroshi; Tushar Bandgar; Anurag R Lila; Swati Sachin Jadhav; Shruti Khare; Shailesh V Shrikhande; Shinya Uchino; Abhay N Dalvi; Nalini S Shah
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

Review 2.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

3.  Impact of "Tailored" Parathyroidectomy for Treatment of Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1.

Authors:  Kiyomi Horiuchi; Momoko Sakurai; Kento Haniu; Erin Nagai; Hiroki Tokumitsu; Yusaku Yoshida; Yoko Omi; Akiko Sakamoto; Takahiro Okamoto
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

4.  Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of 18F-Fluorocholine PET/CT in MEN1 Syndrome.

Authors:  Saurabh Arora; Nishikant Avinash Damle; Averilicia Passah; Madhav Prasad Yadav; Sanjana Ballal; Vivek Aggarwal; Yashdeep Gupta; Praveen Kumar; Madhavi Tripathi; Chandrasekhar Bal
Journal:  Nucl Med Mol Imaging       Date:  2018-05-02

Review 5.  [Asymptomatic primary hyperparathyroidism : Operation or observation?]

Authors:  Katja Gollisch; Heide Siggelkow
Journal:  Internist (Berl)       Date:  2021-03-12       Impact factor: 0.743

6.  Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Authors:  T Weber; C Dotzenrath; H Dralle; B Niederle; P Riss; K Holzer; J Kußmann; A Trupka; T Negele; R Kaderli; E Karakas; F Weber; N Rayes; A Zielke; M Hermann; C Wicke; R Ladurner; C Vorländer; J Waldmann; O Heizmann; S Wächter; S Schopf; W Timmermann; D K Bartsch; R Schmidmaier; M Luster; K W Schmid; M Ketteler; C Dierks; P Schabram; T Steinmüller; K Lorenz
Journal:  Langenbecks Arch Surg       Date:  2021-04-21       Impact factor: 3.445

Review 7.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

8.  Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy.

Authors:  Naris Nilubol; Allison B Weisbrod; Lee S Weinstein; William F Simonds; Robert T Jensen; Giao Q Phan; Marybeth S Hughes; Steven K Libutti; Stephen Marx; Electron Kebebew
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

Review 9.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

10.  Pericardial Type 1 Parathyromatosis: A very rare cause of primary hyperparathyroidism.

Authors:  O Altin; R Sari
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Oct-Dec       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.